Skip to main content

Table 1 Opioid Treatment Program naloxone survey results pre-training at baseline

From: Barriers to and recommendations for take-home naloxone distribution: perspectives from opioid treatment programs in New Mexico

 Study sites
 *SITE 1*SITE 2*SITE 3*SITE 4*SITE 5Site 6Site 7Site 8Total (%)
Training Participation #131411581151178
Question 1: Are you aware of NM’s HB 370?
 Yes2081440120 (25.6%)
 No1014344751057 (73.1%)
No answer1       1 (1.3%)
Question 2: Do you currently prescribe or provide take-home naloxone to your patients? (choose all that apply)
 Write Rx2  34   9 (10.7%)
 Provide take-home 19 5   15 (17.8%)
 Ask pts to go to pharmacy so that a pharmacist prescribes it623 32 117 (20.3%)
 None of the above511121851043 (51.2%)
Question 3: Of the following, which are barriers to dispensing naloxone at your opioid treatment program? (choose all that apply)
 Affordability1232132317 (19.8%)
 No mechanism for reimbursement  1 1  24 (4.7%)
 Unsure what type of naloxone to prescribe (nasal, auto-injector, generic)     11 2 (2.3%)
 Time to educate patients23 2212214 (16.3%)
 Patient refusal121 5  110 (11.6%)
 Lack of patient medical history  1    12 (2.3%)
 Concerns with liability 4   2 39 (10.5%)
 Inadequate supply311 13  9 (10.5%)
 Belief that it promotes heroin and/or prescription drug abuse      112 (2.3%)
 None of the above*35 1121417 (19.8%)
Focus group participation #69756n/an/an/a33
  1. *Sites in all capitals and underline (SITE 1, SITE 2, etc.) indicate sites that participated in follow-up focus groups to assess THN distribution